There are currently 23 active clinical trials seeking participants for Healthy Participants research studies. The states with the highest number of trials for Healthy Participants participants are California, Florida, Texas and Kansas.
Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg
NCT06348303
Recruiting
Every participant will receive Metaxalone in two (2) stages, one week after the other. A single dose of each Metaxalone dose will be taken one (1) time after a high fat meal which must be eaten within 30 minutes. Every participant will be given written tests to measure drowsiness, reaction time and thinking process and will also be asked to take walking tests to assess fall risk. Participation in this study will last approximately 2-4 weeks.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/05/2024
Locations: ClinOhio Research Institute, Columbus, Ohio
Conditions: Healthy Participants
Register for Updates
A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants
NCT06846528
Recruiting
The purpose of this study is to assess the pharmacokinetics (PK) of AZD2389 when administered alone and in combination with itraconazole in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/27/2025
Locations: Research Site, Brooklyn, Maryland
Conditions: Healthy Participants
Register for Updates
A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants
NCT06502379
Recruiting
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of AZD8965 via single and multiple ascending doses in healthy participants (including Japanese and Chinese participants), and to assess the effect of food on the safety, tolerability, and PK of orally administered AZD8965.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/25/2025
Locations: Research Site, Glendale, California
Conditions: Healthy Participants
Register for Updates
A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants
NCT06727136
Recruiting
The main purpose of the study is to characterize the systemic pharmacokinetic (PK) parameters (plasma, whole blood) of tebipenem (TBP) pharmacologically active moiety of tebipenem-pivoxil-hydrobromide (TBP-PI-HBr) and its urinary excretion at different dose levels in healthy participants. The study also aims to assess the plasma and urine PK parameters of SPR1349, a major metabolite of TBP.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/25/2025
Locations: Medical Facility, Salt Lake City, Salt Lake City, Utah
Conditions: Healthy Participants
Register for Updates
A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults
NCT06723756
Recruiting
This study aims to assess the bioequivalence of the total systemic exposure and safety of budesonide, glycopyrronium, and formoterol (160/14.4/4.8 µg/actuation) when administered as BGF MDI HFO compared with BGF MDI HFA in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/21/2025
Locations: Research Site, Brooklyn, Maryland
Conditions: Healthy Participants
Register for Updates
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese
NCT06132841
Recruiting
A study in healthy male and female participants of non-childbearing and childbearing potential who have overweight or obesity
Gender:
ALL
Ages:
Between 18 years and 142 years
Trial Updated:
03/14/2025
Locations: Research Site, Glendale, California +4 locations
Conditions: Healthy Participants
Register for Updates
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants with Hemophilia a or Hemophilia B)
NCT06349473
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, with or without inhibitors (Part B).
Gender:
MALE
Ages:
Between 18 years and 60 years
Trial Updated:
03/11/2025
Locations: California Clinical Trials Medical Group (CCTMG), Glendale, California +5 locations
Conditions: Healthy Participants, Hemophilia A, Hemophilia B
Register for Updates
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
NCT06564389
Recruiting
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/28/2025
Locations: Anaheim Clinical Trials, LLC, Anaheim, California
Conditions: Healthy Participants, Atopic Dermatitis
Register for Updates
Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Food Effect of Oral INCB000631 to Healthy Adult Participants
NCT06775327
Recruiting
This study will be conducted to assess the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics, and Food Effect of INCB000631 When Administered Orally to Healthy Adult Participants.
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
02/28/2025
Locations: Celerion, Inc, Lincoln, Nebraska
Conditions: Healthy Participants
Register for Updates
A Study of LY4060874 in Healthy Participants
NCT06709820
Recruiting
The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants. Study participation may last up to 22 weeks and up to approximately 16 study visits.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/27/2025
Locations: Fortrea, Inc., Dallas, Texas +1 locations
Conditions: Healthy Participants
Register for Updates
A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants
NCT06138795
Recruiting
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD2389 following single and multiple dose administration (SAD/MAD) to healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/24/2025
Locations: Research Site, Glendale, California
Conditions: Healthy Participants
Register for Updates
A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults
NCT06851871
Recruiting
The purpose of this study is to evaluate the bioequivalence between immediate release tablets and minitablets of Deucravacitinib (BMS-986165), and the effect of food and pH on the drug levels of the minitablets in healthy adults.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/24/2025
Locations: Local Institution - 0002, Austin, Texas +1 locations
Conditions: Healthy Participants
Register for Updates